The human protein Elafin plays a key role against the inflammatory reaction typical of Celiac disease and researchers have developed a probiotic bacterium able to deliver Elafin in the gut of mice.
Celiac disease is an auto-immune pathology that occurs in individuals genetically predisposed to gluten intolerance. Affected people do not harbor the enzymes required to degrade gluten during digestion and inflammatory reactions are induced by this abnormal digestion which can lead to the destruction of the gut barrier that is essential for nutrients absorption.
Celiac disease causes chronic abdominal pain (diarrhea, cramps…) and predisposes to certain cancers (small intestine, lymphoma). Its prevalence is estimated between 1/500 and 1/300; no curative treatment currently exist and the only solution is a lifelong gluten-free diet.
Scientists from the French National Institute for Agricultural Research (INRA) and the French National Institute of Health and Medical Research (INSERM), along with Canadian and Swiss colleagues, have shown that Elafin is less abundant in patients with celiac disease than in healthy people. They identified that Elafin is capable of preventing the destruction of the gut barrier during inflammation, and that Elafin is able to interact with enzymes responsible for the abnormal breakdown of gluten: transglutaminase-2.
Consequently, Elafin reduces gluten toxicity.
These observations led the scientists to propose a way to deliver the missing Elafin in celiac patients with help of a harmless bacterium that is often present in food: a lactic bacterium strain (Lactococcus lactis), that scientists transformed in order to express Elafin.
The use of this strain, developed by the same teams from INRA and INSERM, enables a targeted and local production of Elafin, and represents a recent and innovative strategy. The first pre-clinical results pave the way to new therapies for Inflammatory Bowel Disease or IBD (no curative treatment exist).
In the present study, the scientists have administered this bacterium to gluten intolerant mice. They showed that the Elafin delivered by the probiotic decreases significantly the inflammatory reaction.
This strategy, patented by INRA in May 2013, opens promising prospects to treat celiac disease and gluten intolerance in general. The next step will consist in defining the mechanisms underlying the positive effects of elafin in celiac disease, and in the identification of bacteria that naturally produce proteins with anti-inflammatory properties similar to elafin.
Citation: Heather J. Galipeau, Michelle Wiepjes, Jean-Paul Motta, Jessica D. Schulz, Jennifer Jury, Jane M. Natividad, Ines Pinto-Sanchez, Daniel Sinclair, Perrine Rousset, Rebeca Martin-Rosique, Luis Bermudez-Humaran, Jean Christophe Leroux, Joseph Murray, Edgardo Smecuol, Julio C. Bai, Nathalie Vergnolle, Philippe Langella and Elena F. Verdu, 'Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders', American Journal of Gastroenterology, 8 April 2014. DOI : 10.1038/ajg.2014.48
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Sexual Fantasies: Threesomes Are Normal, Golden Showers Not So Much
- Resveratrol Reverses Benefits Of Exercise - Study
- The Vampire Deer Of Afghanistan
- Aging Brains Aren't Necessarily Declining Brains
- Okay With Disgusting Images? You Vote This Way 95 Percent Of The Time
- Cui Bono? B-corporations And The University
- Information-Theoretic Security: Creating 21st Century Cryptography Standards
- "It's vital to understand that while crapping where you eat is not linked to having conservative..."
- "16 people who were originally doing less than 30 minutes exercise a day then did how much low volume..."
- "Trouble is without citations this article reads like a slew of anecdotes. It begins promisingly..."
- "Do you work for Hank? Or do you just parrot his line of bullshit, and try to legitimize it with..."
- Two-faced anti-GMO groups: Block crop and food innovations then claim Big Ag prevents GMO innovations
- Why support erodes for GMO labeling (Hint: It’s not because of spending by Big Ag)
- Genetic “hall of mirrors” with large palindromes, yet smaller: What’s mighty about the mouse
- Gut bacteria an easy scapegoat for disease, but connections hard to prove
- Vermont Rube Goldberg-like GMO labeling law exempts GMO filled natural supplements
- Downside to GMOs: Yields have become so good, they exceed processing capacity
- More penalties on the way for hospitals that treat the poor? New U-M study suggests so
- Cancer cell fingerprints in the blood may speed up childhood cancer diagnosis
- Study of Chile earthquake finds new rock structure that affects earthquake rupture
- Tracking a gigantic sunspot across the Sun
- Massive geographic change may have triggered explosion of animal life